# IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

> **NCT04933799** · PHASE2 · UNKNOWN · sponsor: **Giovanni Franchin, M.D, Ph.D** · enrollment: 68 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** PF-06650833
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04933799
- **Lead sponsor:** Giovanni Franchin, M.D, Ph.D
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-06
- **Primary completion:** 2022-03-06
- **Final completion:** 2022-05-06
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933799, "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04933799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*